natgillin/translations-raw huggingface dataset:
ring A is an optionally substituted aryl or an optionally substituted heteroaryl; 
R, je izborno supstituirani heteroaril, i R je H ili izborno supstituirani alkil.
However, since in most cases of abuse it is still necessary to pulverise the dosage form comprising an active ingredient suitable for abuse, it was the object of the present invention to complicate or prevent the pulverisation preceding abuse of the dosage form comprising the agents conventionally available for potential abuse and accordingly to provide a dosage form for active ingredients with abuse potential which ensures the desired therapeutic effect when correctly administered, but from which the active ingredients cannot be converted into a form suitable for abuse simply by pulverisation. 
Budući da je u većini slučajeva za zlouporabu potrebno pulveriziranje oblika davanja koji sadrži tvari prikladne za zlouporabu, zadaća ovog izuma bila je da se pulveriziranje oblika davanja koje prethodi zlouporabi oteža, odnosno spriječi sredstvima koja uobičajeno stoje na raspolaganju potencijalnom zlorabitelju i time stavi na raspolaganje kruti oblik davanja djelatnih tvari s potencijalom za zlouporabu, koji kod propisane aplikacije jamči željeno terapeutsko djelovanje, iz kojeg se oblika međutim djelatne tvari ne mogu jednostavnim pulveriziranjem prevesti u oblik koji je prikladan za zlouporabu.
The compound for use of claim 9, wherein the voltage-gated sodium ion channel is NaV 1.7. 
Spoj za uporabu prema patentnom zahtjevu 23, naznačen time što od napona ovisan natrijev ionski kanal je NaV 1.7.
The pharmaceutical composition according to claim 18, wherein a ratio of the total mass of the suspending particles to the total mass of the active agent particles is selected from between 3:1 and about 15:1 and between 2:1 and 8:1. A pharmaceutical composition according to claim 1, comprising: a suspension medium comprising a pharmaceutically acceptable HFA propellant; 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se omjer ukupne mase najmanje jedne vrste suspendirajućih čestice i ukupne mase najmanje jedne vrste čestica sredstva bira između iznad 1 i do 1,5, do 5, do 10, do 15, do 17, do 20, do 30, do 40, do 50, do 60, do 75, do 100, do 150, te do 200.
Method according to any one of the preceding claims, characterized in that the adjustment of the current is carried out within a predetermined adjustment time window, in particular within 5 - 300ms, preferably within 10 - 15 ms. 
Metoda prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što u slučaju podešavanja struje ka višim vrijednostima, podešavanje struje se vrši postepeno u okviru unaprijed određenog vremenskog prozora za podešavanje, naročito unutar 5 - 300 ms, poželjno unutar 10 - 15 ms.
After stirring at room temperature for 4 hours, the reaction mixture is diluted with DCM (3 ml) and stirred vigorously for 10 minutes. 
Nakon miješanja 4 sata pri sobnoj temperaturi, reakcijsku smjesu se razrijedi s DCM-om (3 ml) i miješa se snažno 10 minuta.
A dry powder formulation for use in a dry powder inhaler (DPI) to deliver by inhalation a combination of micronized particles of glycopyrronium bromide, beclometasone dipropionate, and formoterol fumarate dihydrate as active ingredients in a combined therapeutically effective dose comprised of 100 to 500 µg, said formulation comprising: 
Formulacija suhog praška za upotrebu u inhalatoru za suhi prašak (DPI) za isporuku inhalacijom kombinacije mikroniziranih čestica glikopironijeva bromida, beklometazon-dipropionata, te formoterol-fumarat dihidrata kao aktivnih tvari u kombiniranoj terapijski učinkovitoj dozi koja sadrži od 100 do 500 ug, rečena formulacija sadrži:
A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 14 ili njenu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivi nosač.
More particularly, the present invention is directed to new and useful taxane analogs and methods for producing them. 
Još posebnije, predmetni izum je usmjeren na nove i korisne analoge taksana i postupke za njihovu proizvodnju.
wherein the binding compound binds to the conformational human APRIL epitope SMPSHP, and preferably to IRSMPSHPDRA, and wherein the binding compound fully blocks the binding of APRIL with human TACI and at least partially blocks the binding of APRIL with human BCMA. 
pri čemu se vezujući spoj veže za konformacijski humani APRIL epitop SMPSHP, preferirano za IRSMPSHPDRA, a pri čemu vezujući spoj potpuno blokira vezanje APRIL sa humanim TACI i barem djelomično blokira vezanje APRIL s humanim BCMA.
The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. 
Push-fit kapsule mogu sadržavati aktivne sastojke u smjesi s punilom, poput laktoze, vezivima, poput škrobova, i(li) mazivima, poput talka ili magnezijevog stearata, a izborno i stabilizatorima.
Lithium hydroxide (1.61 g, 67.39 mmol) in water (95 mL) is added and the reaction allowed to stir at room temperature for about 2 h. 
Doda se litijev hidroksid (1,61 g, 67,39 mmol) u vodi (95 ml), a reakcijsku smjesu ostavi otprilike 2 sata miješati na sobnoj temperaturi.
A conjugate according to claim 17 or 18, wherein said cell binding agent is chosen from monoclonal antibodies; single chain antibodies; fragments of antibodies such as Fab, Fab', F(ab')2 and Fv, interferons; peptides; lymphokines such as IL-2, IL-3, IL-4, IL-6; hormones such as insulin, TRH (thyrotropin releasing hormones), MSH (melanocyte-stimulating hormone), steroid hormones, such as androgens and estrogens; growth factors and colony-stimulating factors such as EGF, TGFa, insulin like growth factor (IGF-I, IGF-II) G-CSF, M-CSF and GM-CSF; vitamins, such as folate and transferrin. 
Konjugat u skladu s patentnim zahtjevom 3 do 8, naznačen time što se navedeno sredstvo za vezanje na stanicu bira između monoklonskih protutijela; kimernih protutijela; humaniziranih protutijela; posve ljudskih protutijela; jednolančanih protutijela; fragmenata protutijela, poput Fab, Fab', F(ab'), i Fv, interferona; peptida; limfokina, poput 1IL-2, IL-3, IL-4, IL-6; hormona, poput inzulina, TRH (tireooslobađajućih hormona), MSH (melanostimulirajućeg hormona), steroidnih hormona, poput androgena i estrogena; čimbenika rasta i čimbenika stimulacije kolonija, poput EGF, TGFa, inzulinu sličnog čimbenika rasta (IGF-L, IGF-Il) G-CSF, M-CSF i GM- CSF; vitamina, poput folata i transferina.
Compared to oligofructose derived from inulin, fructo-oligosaccharide has the advantage that its reducing sugar groups, i.e. 
U usporedbi s oligofruktozom dobivenom iz inulina, prednost je frukto-oligosaharida što snjihove skupine reducirajućih šećera, tj.
is a straight or branched aliphatic carbon chain of 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 2 carbons in length. 
je ravan ili razgranat alifatni lanac ugljika duljine od 1 do 6, 1 do 5, 1 do 4, 1 do 3 ili 2 ugljika.
A compound according to any preceding claim, wherein R2 and R'2, together with the nitrogen atom to which they are linked, form a morpholinyl group. 
Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da R, i R2, zajedno sa atomom dušika na koji su spojeni, formiraju morfolinilnu skupinu.
An antibody or antigen binding fragment according to claim 1 or 2, which specifically binds hIL-6R with a KD of 300 pM or less, as measured by surface plasmon resonance. 
Antitijelo ili njegov fragment koji se veže na antigen u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da specifično veže hIL-6R konstantom Kd od 300 pM ili manjom izmjereno površinskom plazmonskom rezonancijom.
Another aspect of the invention relates to a probiotic composition comprising the bacterial species Roseburia hominis. 
Probiotski sastav koji sadrži bakterijsku vrstu Roseburia hominis.
the value of the data item (D1) is updated. 
- < ažurira se vrijednost podatkovne stavke (D1).
a second light chain and a second heavy chain of a second antibody which specifically binds to CD3, and wherein variable domains VL and VH in the second light chain and second heavy chain of the second antibody are replaced by each other; and wherein 
drugi laki lanac i drugi teški lanac drugog antitijela koje se specifično veže za CD3, i gdje su varijabilne domene VL i VH u drugom lakom lancu i drugom teškom lancu drugog antitijela zamijenjene jedna drugom i
For example, flow rates may vary depending on (i) the type of solid support for cultivation of anchorage-dependent cells; and (ii) the porosity of the solid support. 
Primjerice, stope protoka mogu varirati u ovisnosti o (1) tipu krute potpore za uzgoj stanica koje potrebuju pričvršćivanje; 1 (11) poroznosti krute potpore.
Shaft 52 extends through the central bore defined in compression spring 24 and terminates at its in-use lowermost end in a threaded portion 53 . 
Osovina 52 se produžava kroz centralni otvor unutar kompresijske opruge 24 i završava prilikom korištenja na najnižem dijelu navojnog dijela 53.
In embodiment 9, the invention pertains to prodrug of compound of Formula III or IV, i.e., compounds of Formula I or II according to embodiment 1, 2 or 3, wherein R1 is Me, Et or is selected from a group of the following Formulae: 
Spoj prema zahtjevu 1, 2 ili 3, naznačen time, da R' je Me, Et, ili je odabran iz skupine od sljedećih Formula: S s
palliating symptoms of the condition. 
ublažavanja simptoma uvjeta.
As a result, the relevant cavity can be closed effectively. 
Kao posljedica toga, predmetna šupljina može biti učinkovito zatvorena.
In a multiple-feed circular machine, the first rows of knitting 1 can be formed at feeds or drops that are alternated, in the arrangement of the feeds or drops around the axis of the needle cylinder, with feeds or drops that are used to form the second rows of knitting 2. 
U kružnom stroju s višestrukim dovodom, neparni redovi pletenja 1 mogu se oblikovati na dovodima ili transporterima koji su naizmjenični, u rasporedu dovoda ili transportera oko osi cilindra s iglama, pri čemu se dovodi ili transporteri upotrebljavaju za oblikovanje parnih redova pletenja 2.
The process according to any of claims 1 to 14, characterised in that the C8 to C24 aliphatic carboxylic acid(s) employed in step (b) are selected among the saturated, linear aliphatic carboxylic acids, the hydroxylated aliphatic carboxylic acids, and preferably among the stearic and/or palmitic and/or myristic and/or lauric acids or mixtures thereof, and most preferably stearic and/or palmitic acid. 
Uporaba proizvoda prema bilo kojem zahtjevu od 1 do 13 naznačena time da je za miješanje i/ili ekstrudiranje i/ili slaganje i/ili puhanje plastičnih materijala, te poželjno za poliolefine ili termoplastike kao što su polietilen (PE), polipropilen (PP), poliuretani (PU) i polivinilklorid (PVC).
To avoid these complications, IL-2 compositions of the invention for DLS measurement are preferably free from particles with a diameter greater than about 1µm (e.g. 
Da se izbjegnu ove komplikacije, sastavi IL-2 iz izuma za DLS mjerenje su pogodno bez čestica s promjerom većim od oko 1um (na pr.
In another embodiment, the antibody or antigen binding fragment thereof increases a serum biomarker of bone deposition selected from the group consisting of as total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, and type-I procollagen (C-terminal/N-terminal). In another embodiment, the antibody or antigen binding fragment thereof inhibits bone resorption. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što protutijelo ili njegov ulomak koji veže antigen povećava biomarker seruma odlaganja kosti odabran iz skupine koju čine ukupna alkalna fosfataza, alkalna fosfataza specifična za kosti, osteokalcin, i prokolagen tip-I (C-terminalni/N-terminalni).
A device according to any of the preceding examples, wherein the fluid outlet (17) is connectable to a water tank for flushing wastewater away from the internal organ via said interior passage (10). 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, kod kojega je izlazni otvor za fluid (17) spojen na spremnik s vodom radi uklanjanja otpadne vode od ispiranja iz unutarnjeg organa kroz navedeni unutarnji prolaz
An inhaler according to claim 1, wherein the manifold is arranged such that, in use, air is drawn into the manifold solely through the air inlet. 
Inhalator u skladu s patentnim zahtjevom 1, pri čemu je cjevovod postavljen tako da je, u uporabi, zrak uvučen u cjevovod jedino kroz ulaz zraka (125).
In some embodiments, provided herein is a pharmaceutically acceptable transdermal composition comprising: octanol, lauroglycol, organic acid, optionally a basic amino acid, and an active agent comprising an amine moiety or an amide moiety. 
Farmaceutski prihvatljiv transdermalni sastav iz zahtjeva 1, naznačeno time da je masni alkohol oktanol, terpen je limonen, aktivni sastojak ima amino skupinu, te sastav dalje sadrži osnovnu aminokiselinu.
The compound for use according to Claim 1, wherein said chronic hyperkinetic movement disorder is Tourette's syndrome. 
Spoj za uporabu prema zahtjevu 1, naznačen time da navedeni kronični poremećaj hiperkinetičkog pokreta je Touretteov sindrom.
The hole has a diameter of 2.5 mm and a depth of 5 mm and is intended to simulate a cavity. 
Otvor je imao promjer od 2.5 mm 1 dubinu od 5 mm i namjera je bila da bude model za rupu.
A safety glove comprising at least one protective element or attachment which is glued or fixed to the top dorsal part of at least one of the fingers of said glove and wherein said protective element or attachment consists of a hard, resistant piece with a half-round shape, closed on its end and open on the opposite end and partly on its lateral sides. 
Zaštitna rukavica (2), naznačena time što sadrži najmanje jedan zaštitni element ili dodatak (1) u skladu s patentnim zahtjevom 1, gdje element ili dodatak (1) je zalijepljen ili pričvršćen na gornji dorzalni dio najmanje jednog od prstiju navedene rukavice.
In some embodiments, the invention provides a method of treating a mammal having a cancer characterized by having a defect in the homologous recombination (HR) pathway of double-stranded DNA repair, comprising administering to said mammal a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. 
Spoj prema bilo kojem zahtjevu od 1-5, ili farmaceutski pripravak prema bilo kojem zahtjevu od 6-8, naznačen time da je za uporabu za liječenje sisavca koji ima rak koji se odlikuje time da ima defekt u putu popravka homologne rekombinacije (HR) dvolančane DNA
The assembly of claim 8, wherein the portable gas canister comprises an active pharmaceutical ingredient including one of nitric oxide, with a concentration in the range of approximately 50 ppm to 10,000 ppm; carbon monoxide with a concentration in the range of approximately 500 ppm to 20,000 ppm; or, a chalcogenide compound, and an inactive carrier gas comprising at least one of N2 and O2. An indexed drug containment device assembly for a drug delivery and regulation device, the indexed drug containment device assembly comprising: 
Indeksirani uređaj za ograničavanje sadržaja lijeka (24) prema zahtjevu 2, naznačen time da: aktivni farmaceutski sastojak sadrži dušikov oksid, neaktivni plin nosač sadrži N>, te je koncentracija u spremniku u rasponu od približno 50 ppm do 10,000 ppm, aktivni farmaceutski sastojak sadrži ugljikov monoksid, neaktivni plin nosač sadrži O,, te je koncentracija u spremniku (28) u rasponu od približno 500 ppm do 20,000 ppm, ili, aktivni farmaceutski sastojak je spoj halkogena u prikladnoj koncentraciji.
the heavy chain Fv fragment of a monovalent Fab forming the antigen-binding domain is linked to one of the polypeptides forming the Fc domain via a CH1 domain and the light chain Fv fragment of the Fab is linked to a CL domain; and the light chain Fv fragment of the Fab forming the CD3-binding domain is linked to the other polypeptide forming the Fc domain via a CH1 domain and the heavy chain Fv fragment of the Fab is linked to a CL domain; 
(ii) Fv fragment teškog lanca jednovalentnog Fab koji tvori domenu za vezanje na antigen je vezan na jedan od polipeptida koji tvore Fc domenu preko domene CH], a Fv fragment lakog lanca Fab je vezan na domenu CL; i Fv fragment lakog lanca Fab koji tvori domenu za vezanje na CD3 je vezan na drugi polipeptid koji tvori Fc domenu preko domene CH], a Fv fragment teškog lanca Fab je vezan na domenu CL;
The antibody conjugate according to claim 14, wherein said agent is a therapeutic or cytotoxic agent and is selected from the group consisting of: an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, toxin, and an apoptotic agent; optionally wherein the anti-mitotic agent is selected from the group consisting of a dolastatin, an auristatin, a maytansinoid, a plant alkaloid, a taxane, and a vinca alkaloid. 
Konjugat protutijela prema zahtjevu 14, naznačen time da navedeno sredstvo je terapeutsko ili citotoksično sredstvo i odabrano je iz skupine koja sadrži: anti-metabolit, sredstvo za alkiliranje, antibiotik, faktor rasta, citokin, antiangiogeno sredstvo, anti-mitotičko sredstvo, antraciklin, toksin, te apoptotičko sredstvo; proizvoljno pri čemu je anti-mitotičko sredstvo odabrano iz skupine koja sadrži dolastatin, auristatin, majtanzinoid, biljni alkaloid, taksan, te vinka alkaloid.
wherein the alcohol is present in the reaction medium in an amount of 25% to 90% by volume, based on the total volume of the reaction medium; wherein the pH employed in step i) is 7.0 to 10.0, when the physiologically active polypeptide is an exendin, oxyntomodulin, GLP-1, GLP-2 or one of the derivatives thereof, and wherein the pH employed in step i) is 4.0 to 10.0 when the physiologically active polypeptide is human insulin or a derivative thereof. 
Formula IV pri čemu je alkohol etanol ili izopropanol; gdje je alkohol prisutan u reakcijskom mediju u količini od 25% do 90% po volumenu, na osnovi ukupnog volumena reakcijskog medija; dok je pH u koraku i) namješten na 7,0 do 10,0, kada je fiziološki djelotvorni polipeptid eksendin, oksintomodulin, GLP-1, GLP-2 ili jedan od njihovog derivata, 1 pri čemu je pH u koraku 1) namješten na 4,0 do 10,0 kada je fiziološki djelotvorni polipeptid ljudski inzulin ili njegov derivat.
A composition according to any one of claims 1 to 14, comprising at least one of the following auxiliaries: surfactants, embittering denaturants (anti-licking), preservatives, spreading aids, penetration or occlusion enhancers, and anti-oxidants. 
Smjesa prema bilo kojem od zahtjeva 1 do 14, koja sadrži barem jednu od sljedećih pomoćnih tvari: surfaktante, denaturans za gorki okus (protiv lizanja), konzervanse, tvari za razmazivanje, pojačivače penetracije ili okluzije i antioksidanse.
a fourth domain VHA being a heavy chain variable domain specific for CD3, wherein in the first and second polypeptide chain the first domain VLA is linked with the second domain VHB by a first linker L1, the second domain VHB is linked with the third domain VLB by a second linker L2 and the third domain VLB is linked with the fourth domain VHA by a third linker L3, wherein the linkers L1, L2 and L3 consist of 6, 7, 8, 9, 10, 11 or 12 amino acid residues, 
četvrtu domenu VHA koja predstavlja varijabilnu domenu teškog lanca specifičnu za prvi antigen A, naznačena time, što VLA je vezana za VHB prvim linkerom L1, VHB je vezana za VLB drugim linkerom L2 i VLB je vezana za VHA trećim linkerom L3; prva domena VLA i četvrta domena VHA su specifične za CD3;
The composition of claim 1 which further comprises compound 5 or a pharmaceutically acceptable salt thereof. 
Kompozicija iz patentnog zahtjeva 1 koja dalje sadrži spoj 5 Kk m6. 7
The method of claim 1, wherein the immunogenic fragment of an HSV-2 UL19 polypeptide has the amino acid sequence set forth in SEQ ID NO:12. 
Smjesa iz bilo kojeg od patentnih zahtjeva 1 do 3, naznačena time, što gD2 sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO:2 ili 3.
Pharmaceutical forms according to any of previous claims comprising at least one of coconut oil, pam oil, nuts, olives, soya beans, seeds, wheat germ, sunflower, seed cotton, beef tallow or sardine oil. 
Farmaceutski oblici prema bilo kojem od prethodnih zahtjeva naznačeni time da sadrže barem jedno od slijedećeg kokosovo ulje, palmino ulje, ulje orašastih plodova, masline, soje, sjemenki, pšeničnih klica, suncokretovo ulje, ulje sjemenski pamuka, goveđi loj ili ulje od sardina.
The liquefied gas treatment system according to claim 1, further comprising a gas-liquid separator (23) configured to separate the BOG, which is decompressed to a gas-liquid mixed state while passing through the decompressing means (22), into a gas component and a liquid component. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 3, naznačen time što pomoćna linija za slanje LNG (1.24) sadrži separator plina od tekućine (46), podešen za razdvajanje teške ugljikovodične komponente od LNG, kako bi se podesilo metanski broj goriva do vrijednosti potrebne za pomoćni motor.
No. 4,686,237, octahydronaphthalenes such as disclosed in U.S. Pat. No. 4,499,289, keto analogs of mevinolin (lovastatin) as disclosed in European Patent Application No. 0,142,146 A2, and quinoline and pyridine derivatives disclosed in U.S. Pat. 
Patentnom br. 4,686,237, oktahidronafialeni, kao što je prikazano u U.S. Patentnom br. 4,499,289, keto analozi mevinolina (lovastin) kao što je prikazano u Europskoj patentnoj prijavi br. 0,142,146 A2 i kinolin i piridin derivati prikazani u U.3.Patentnim brojevima 5,506,219 i 5,691,322.
The method of any one of claims 1 to 8, wherein the juice is a fresh juice, a juice concentrate or a diluted juice. A method of any of claims 1 to 9, wherein the juice is contacted with the cation exchange resin and/or the anion exchange resin and/or the mixed bed of cation and anion exchange resins at an average flow rate of about 2 bv/hr to about 30 bv/hr. 
spajanje djelomično prerađenog soka sa smolom za izmjenu aniona kako bi se proizvelo sastav slatkog soka,npri čemu sastav slatkog soka zadržava barem 60% mogrosida V iz soka kako je utvrđeno tekućinskom kromatografijom visokog tlaka (HPLC), pri čemu je opcionalno sok pružen u koraku (a): svježi sok, i pri čemu je omjer smole za kationsku izmjenu i smole za anionsku izmjenu otprilike 1 prema 1; ili razrijeđeni sok, i pri čemu je omjer smole za kationsku izmjenu i smole za anionsku izmjenu oko 1.4-2 prema 1.
The composition for the use according to claim 9, wherein said disease is selected: from a proliferative disorder selected from hyperplasias, fibrosis, angiogenesis, psoriasis, atherosclerosis, stenosis or restenosis following angioplasty, and other diseases characterized by smooth muscle proliferation in blood vessels; 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od proliferativnog poremećaja izabranog između hiperplazija, fibroze, angiogeneze, psorijaze, ateroskleroze, stenoze ili restenoze nakon angioplastike, i drugih bolesti naznačenih proliferacijom glatkih mišića u krvnim žilama.
six or more additional reliever puffs of albuterol or levalbuterol in a 24 hour period (compared to baseline) on two consecutive days; and a deterioration of asthma requiring: 
(b) šest ili više dodatnih upuhivanja pumpicom albuterola ili levalbuterola tijekom razdoblja od 24 sata (u usporedbi s početnom vrijednosti) dva uzastopna dana; i (Cc) pogoršanje astme koje zahtijeva:
The compound of the invention is also expected to be of use in the treatment of certain GI (gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome). 
Također se očekuje da će spoj prema ovom izumu biti koristan u liječenju izvjesnih GI (gastrointestinalni) poremećaja, poput IBS (sindrom iritabilnog kolona).